Robert McNeil has over 35 years’ experience as an active investor and management participant in seed and early-stage biomedical companies.
He founded Sanderling Ventures in 1979 and has served since then as a Managing Director of the firm’s seven investment partnerships.
Dr. McNeil has been an active investor in over sixty early stage investments for Sanderling Ventures. In each case, close relationships with management and careful understanding of the companies’ technologies have allowed successful development of products at very early stage. Dr. McNeil has played an active role in these seed companies and has helped many graduate to late stage status where they either were purchased or affected public offerings.
Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics in 1972 from the University of California, Irvine.
Michael Dixon has over 18 years’ experience working in an executive role for venture-backed companies.
Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Gemin X he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada.
Prior to Gemin X, Mr. Dixon was Interim COO and Vice President Finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon is also president and chief executive officer at Therillia Development Company.
Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.